GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bioasis Technologies Inc (FRA:107) » Definitions » Shares Outstanding (EOP)

Bioasis Technologies (FRA:107) Shares Outstanding (EOP) : 79.41 Mil (As of Nov. 2022)


View and export this data going back to 2017. Start your Free Trial

What is Bioasis Technologies Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Bioasis Technologies's shares outstanding for the quarter that ended in Nov. 2022 was 79.41 Mil.

Bioasis Technologies's quarterly shares outstanding stayed the same from Aug. 2022 (79.41 Mil) to Nov. 2022 (79.41 Mil).

Bioasis Technologies's annual shares outstanding increased from Feb. 2021 (72.14 Mil) to Feb. 2022 (72.91 Mil). It means Bioasis Technologies issued new shares from Feb. 2021 to Feb. 2022 .


Bioasis Technologies Shares Outstanding (EOP) Historical Data

The historical data trend for Bioasis Technologies's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioasis Technologies Shares Outstanding (EOP) Chart

Bioasis Technologies Annual Data
Trend Feb13 Feb14 Feb15 Feb16 Feb17 Feb18 Feb19 Feb20 Feb21 Feb22
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 51.74 58.59 63.57 72.14 72.91

Bioasis Technologies Quarterly Data
Feb18 May18 Aug18 Nov18 Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 72.14 72.91 79.41 79.41 79.41

Competitive Comparison of Bioasis Technologies's Shares Outstanding (EOP)

For the Biotechnology subindustry, Bioasis Technologies's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bioasis Technologies's Shares Outstanding (EOP) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bioasis Technologies's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Bioasis Technologies's Shares Outstanding (EOP) falls into.



Bioasis Technologies Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Bioasis Technologies  (FRA:107) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Bioasis Technologies Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of Bioasis Technologies's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


Bioasis Technologies (FRA:107) Business Description

Traded in Other Exchanges
N/A
Address
157 Church Street, 19th Floor, New Haven, CT, USA, 06510
Bioasis Technologies Inc is a development stage biopharmaceutical company. It is engaged in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. The company has worked on a blood-brain barrier program and studies disorders in the brain. The company's xB3 program describes its proprietary carrier, for the delivery of therapeutics across the blood-brain barrier and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases. The company's in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.

Bioasis Technologies (FRA:107) Headlines

No Headlines